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Abstract
A highly convergent, enantioselective total synthesis of the potent antitumor agent apoptolidin A,
has been completed. The key transformations include highly selective glycosylations to attach the
C27 disaccharide and the C9 6′-deoxy-L-glucose, a cross metathesis to incorporate the C1-C10
trienoate unit, and a Yamaguchi macrolactonization to complete the macrocycle. Twelve
stereocenters in the polypropionate segments and sugar units were established through
diastereoselective chlorotitanium enolate aldol reactions.
Apoptolidins A-D (Figure 1) are secondary metabolites of Nocardiopsis sp. which are potent,
selective inducers of programmed cell death in rat glia cells transformed with the adenovirus
E1A oncogene. Apoptolidin A was isolated by Hayakawa in 1997, and its structure was
elucidated by a combination of NMR spectroscopy and molecular model techniques.1 The
minor metabolites apoptolidins B, C, and D were recently isolated and identified by Wender.
2,3 Importantly, apoptolidin A has no effect on normal cells at concentrations as high as 88
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apoptolidin A at concentrations of 10 nM.1 This selective activity of cancer therapeutics is a
major factor in minimizing side effects of chemotherapeutic agents.
The apoptolidins have been the subject of intense synthetic and biological4 investigations
because of their potential as agents for the treatment of cancer.5 Two total syntheses of
apoptolidin A,6 several syntheses of the aglycone, known as apoptolidinone,7 including one
from our laboratory,8 a number of partial syntheses,9 as well as selective synthetic
modifications10 have been reported.
Apoptolidin A (1, Scheme 1) is comprised of a macrocyclic lactone and two unusual
carbohydrate units attached through glycosidic linkages at the C9 and C27 hydroxyl groups.
Our highly convergent approach to the synthesis of apoptolidin A focused initially on the
individual preparation of the aglycone, apoptolidinone,8 and the carbohydrate units,9e with
the expectation that the approach to apoptolidinone could be adapted to a synthesis of
apoptolidin A by a late-stage attachment of the sugar units to advanced intermediates in the
apoptolidinone synthesis.
The glycosyl fluoride 4 derived from L-olivomycose and D-oleandrose would be utilized to
attach the required disaccharide at C27 of mixed ketal 2 or a similar advanced intermediate
prior to incorporation of the trienoate 3. Sulfoxide 5 would serve as the glycosylating agent
for the incorporation of the 6′-deoxy-L-glucose unit at C9 either immediately before or after
assembly of the C1-C10 and C10-C28 subunits via a stereoselective olefin cross-metathesis
reaction. Mixed ketal 2 and trienoate 3 were advanced intermediates in our recently reported
synthesis of apoptolidinone.8
The required glycosyl donors 4 and 5 for the incorporation of the sugar units were obtained as
illustrated in Schemes 2 and 3. Each of the individual monosaccharide units were obtained by
de novo synthesis through the application of a chlorotitanium glycolate aldol approach to
establish the C4 and C5 stereocenters of each of the monosaccharides.9e
The necessary glycosyl fluoride 4 was accessed from the protected disaccharide 10 as shown
in Scheme 2. Direct exposure of the hemiacetal 10 to DAST provided the glycosyl fluoride 4
(>10:1 α:β).6c Since the glycosyl fluoride was somewhat unstable, it was utilized in the
subsequent glycosylation of the C27 hydroxyl group without further purification.
The synthesis of 6′-deoxy-L-glucose (the C9 sugar unit) donor 5 was readily accomplished
from lactone 69e (Scheme 3). Protection of the diol as the corresponding TBS ether 7 was
followed by reduction of the lactone with i-Bu2AlH to deliver the protected 6′-deoxy-L-glucose
8. The hemiacetal 8 was converted to mixed acetal 9 ((5:1 α:β) by exposure to PhSSiMe3 in
the presence of ZnI2. The required glycosyl donor 5 was obtained as a 2.5:1 mixture of isomers
in 72% yield by oxidation of the thioacetal with m-CPBA.6c
The asssembly of the four key subunits for the completion of the synthesis of apoptolidin A
began with the modification of mixed ketal 2. Mixed ketal 2 was an advanced intermediate
from the recently completed synthesis of apoptolidinone, and was available in multigram
quantities through 17 synthetic steps involving an interative aldol sequence. 8
The key C11-C28 diene 12 was accessible by either of two sequences from hemiketal 2 as
illustrated in Scheme 4. Attachment of the C27 disaccharide could be accomplished in high
yield (74%) with excellent stereoselectivity (7:1, α:β) by treatment of C27 alcohol 2 with
stannous chloride in the presence of glycosyl fluoride 4. The C13 acetate was selectively
cleaved in the presence of the C19,20 carbonate whereupon the resultant primary alcohol was
oxidized under Swern11 conditions to produce aldehyde 11 in 89% yield. Two sequential
Wittig olefinations completed the synthesis of diene 12 in 80% overall yield. Alternately, the
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diene unit could be incorporated prior to the attachment of the C27 discaccharide. The C27
alcohol 2 was protected as its triethylsilyl ether followed by removal of the C13 acetate and
subsequent oxidation of the alcohol to the aldehyde 13. Stabilized Wittig olefination of the
aldehyde in chlorobenzene at 90 °C was accompanied by cleavage of the C27 TES ether.
Methylenation of the unsaturated aldehyde provided the desired diene alcohol 14.
Stereoselective glycosylation of the C27 alcohol 14 as described previously for alcohol 2
delivered diene 12 in excellent yield.
Completion of the synthesis of apoptolidin A is illustrated in Scheme 5. Exposure of the alkenes
38 and 12 to the Grubbs heterocyclic carbene catalyst [Cl2(Cy3P)(IMes)Ru=CHPh]12 provided
the desired E isomer 15 through a critical complex cross-metathesis8,13 in good yield (>95:5
E:Z by 1H NMR analysis). An attempted cross metathesis reaction failed when the reaction
was performed after the glycosidation of the C9 oxygen. To complete the synthesis of
apoptolidin A, attachment of the sugar unit at C9 and macrolactonization were required. A
mixture of alcohol 15 anhydride and sulfoxide 5 was exposure to triflic stereoselectively
providing the glycoside 16. Treatment of the ester 16 with LiOH at room temperature rapidly
cleaved the carbonate group and eventually the ester, to give a good yield of the desired seco
acid. Regioselective macrolactonization at C19 proceeded smoothly under Yamaguchi’s
conditions to deliver the macrolactone.14 Finally, cleavage of the silyl ethers and hydrolysis
of the mixed methyl acetal were effected in one operation using H2SiF6 to furnish apoptolidinon
A (1). Synthetic apoptolidin A was identical to an authentic sample.
The successful total synthesis utilized diastereoselective chlorotitanium aldol reactions to
establish twelve (carbons 4′,5′; 4′′,5′′; 4′′′,5′′′, 8,9; 22, 23; and 24, 25) of the 24 stereocenters
of apoptolidin A and exploited a complex cross metathesis to assemble the two major fragments
and construct the C10-C13 diene unit.
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Scheme 1. Retrosynthesis for Apoptolidin A
Crimmins et al. Page 5













Scheme 2. Synthesis of the C27 Disaccharide
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Scheme 3. Synthesis of the C9 Sugar Unit
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Scheme 4. Attachment of the C27 Disaccharide
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Scheme 5. Synthesis of Apoptolidin A
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Structure of the Apoptolidins
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